Minerva Neurosciences (NERV) Operating Leases (2019 - 2020)
Minerva Neurosciences (NERV) posted Operating Leases of $16288.0 for Q2 2020, down 74.69% on a QoQ basis from $64350.0 in Q1 2020, and down 91.9% year-over-year from $201066.0 in Q3 2019.
Minerva Neurosciences (NERV) Operating Leases (2019 - 2020) Analysis & Trends
Minerva Neurosciences' Operating Leases history runs 2 years deep, the most recent figure standing at $16288.0 for Q2 2020.
- Quarterly Operating Leases fell 91.9% year-over-year to $16288.0 in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $16288.0 (down 91.9% YoY) and the FY2019 annual result came in at $111229.0, changed N/A from the prior year.
- Operating Leases was $16288.0 for Q2 2020 at Minerva Neurosciences, down from $64350.0 in the prior quarter.
- Across five years, Operating Leases topped out at $243115.0 in Q1 2019 and bottomed at $16288.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 16,288.00 |
| Mar 31, 2020 | 64,350.00 |
| Dec 31, 2019 | 111,229.00 |
| Sep 30, 2019 | 156,956.00 |
| Jun 30, 2019 | 201,066.00 |
| Mar 31, 2019 | 243,115.00 |